Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15238368 | 0.93 | KDR (0.71) | KDRPDGFRB | |
| SCHEMBL15238499 | 0.89 | KDR (0.67) | KDRPDGFRB | |
| SCHEMBL15238494 | 0.89 | KDR (0.74) | KDRPDGFRB | |
| SCHEMBL15238672 | 0.88 | KDR (0.75) | KDRPDGFRB | |
| SCHEMBL15238763 | 0.87 | KDR (0.68) | KDRPDGFRB | |
| SCHEMBL15238554 | 0.85 | KDR (0.69) | KDRPDGFRB | |
| SCHEMBL15238311 | 0.85 | KDR (0.69) | KDRPDGFRB | |
| SCHEMBL15238779 | 0.84 | KDR (0.72) | KDRPDGFRB | |
| SCHEMBL15238735 | 0.83 | KDR (0.64) | KDRPDGFRB | |
| SCHEMBL15238808 | 0.82 | KDR (0.62) | KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2825537-B1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN INC (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2825537-B1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9388176-B2 | Method of treating conditiions with kinase inhibitors | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388176-B2 | Method of treating conditiions with kinase inhibitors | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-8889870-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889870-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2013138393-A1 | METHOD OF TREATING OPHTHALMIC CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138396-A1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | KDR 349/4885PDGFRB 603/4885 |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | KDR 349/4885PDGFRB 603/4885 |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | CDK5, MAP3K1, ALDH1A2 | KDR 520/4885PDGFRB 363/4885 |
| US-20130237538-A1 | KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | KDR 362/4885PDGFRB 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.